Previous observational studies have suggested that higher Hb levels do not increase the mortality rate [15,16]; however, randomized control trials have shown that high Hb levels worsen clinical outcomes by increasing the risks of stroke, hypertension, and vascular access thrombosis [17–20] but do not increase the mortality rate. The gene discussed is GSTM1; the disease is stroke disorder.